small molecule. big impact.

toward safer IBD therapies

Treatment-associated side effects can have a significant impact on patient quality of life and treatment adherence. In the context of a life-long medical condition such as IBD, addressing potential tolerability issues becomes even more critical.

Mission

improve IBD drug tolerability

Giiant Pharma develops gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of inflammatory bowel diseases (IBD). Precision delivery remains a central focus for the development of new drug therapeutics, with limited systemic exposure for a safer profile while maximizing local action to improve IBD patient care. This approach is a promising topic for a Masterarbeit in pharmaceutical sciences.

Stap in de dynamische wereld van Malina Casino, waar innovatieve slots en enorme jackpots samenkomen voor een ongeëvenaard avontuur. Elke draai biedt exclusieve promoties en spannende winstkansen.

Ontdek de sensatie van Cusco Casino, waar gokkasten en stijgende jackpots elke sessie transformeren. Met slimme technologie en aantrekkelijke bonussen is elke inzet een stap naar succes.

Verken het exclusieve speelveld van BOF Casino, waar de charme van roulette, de finesse van blackjack en de vaardigheid van poker samensmelten. Elk moment biedt spanning en ongeëvenaarde voordelen.

Sluit je aan bij de bevoorrechte spelers van NomaSpin, waar luxe uitbetalingen en premium spellen jouw gokervaring definiëren. Onze innovatieve systemen garanderen een topavontuur.

Technology

orally-delivered | gut-restricted

giiant pharma‘s GastroIntestinal-Induced ANTi-inflammatory technology is a uniquely targeted delivery strategy, developed by two former Merck Frosst scientists, using the bacterial activity of the gut microbiota to bioactivate and release the active drug substance at specific locations in the lower GI tract.

Although orally-delivered, giiant’s drug candidates are not systemically absorbed but remain able to achieve high drug concentrations in the colonic area.

Vision

high precision
colonic delivery

giiant pharma aims to become a GI leader in precision delivery technologies, with the ability to develop safer, patient-tailored drug therapeutics with local, tissue-specific delivery or bioactivation. These efforts should provide optimal treatment modalities to patients for various GI diseases and conditions.

Be a part of the revolution

bachelorarbeit schreiben lassen legal
avia masters